BTW, look at SLIDE 14: YMI put in a slide about Merck and Takeda's partnership re Matuzumab and financials. Why? Has nothing to do with the overall YMI corp presentation. My take: they are sending the subliminal message that there will be a substantial partnership(s) for Nimotuzumab. And why not...
I know, I know. If they do deliver on their promises, I will be pleased.
I have to admit I am frustrated because this company is so great--why the hell are we still at ~$3.00? I see total POS companies with a single product in stage 2 that are worth 3 to 5 times YMI.
Regarding slide 14: Have you had a chance to listen to the R&R Conference? Allan's commentary on the Merck/Takeda slide was not-too-subliminal. Let's hope there is something similar in the cards for YMI. Soon would be nice.
Just needed to vent, anyway. Part of my problem is that I was growing used to big returns in a few months--it's been a very good two years for my biotech portfolio. Now I just need to relearn patience.
I share your frustration...most of my shares are now long-term cap gains.
I take comfort in knowing that ANY of their products, if successful, will markedly increase the paltry market cap. Taken together, they will add up substantially.
I also like the odds of chasing a 140% OS sub-group to achieve a 50% benefit in a pivotal trial. And they still maintain their belief in "mid-2006." I think it foolish to believe the company is totally-blinded, even if they only have anecdotal evidentiary data.